Home > Newsletters > Drug Industry Daily > Bayer Reports Positive Phase III Results for Potential Stomach Cancer Drug
Drug Industry Daily
June 5, 2012 | Vol. 11 No. 110
Bayer Reports Positive Phase III Results for Potential Stomach Cancer Drug
Bayer HealthCare is planning on filings this year for regorafenib after Phase III success in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease had progressed after treatment with Novartis’ imatinib and Pfizer’s sunitinib.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.